Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Kyowa Kirin Recalling Mitomycin over Unauthorized Manufacturing Method, Supply Won’t Resume until 2021
Kyowa Kirin has launched a voluntary recall of its cancer drug mitomycin after it was found to have been manufactured by an unauthorized method, which cannot ensure sterile APIs, with its supply unlikely to restart before 2021. As no generic…
To read the full story
Related Article
- Kyowa Kirin Files Intas-Licensed Mitomycin for Cancer Use in Japan
October 19, 2022
- All FAD Agents in Japan to Be Discontinued as Kyowa Hakko Bio Quits API Production
June 9, 2022
- Kyowa Hakko Bio’s GMP Breach Triggers Shipment Curbs, Stockouts at Astellas, Kowa; Impact Could Reverberate Further
June 3, 2020
- Kyowa Hakko Bio Staffers Hid GMP Violations, Fearing Supply Halt: Report
February 4, 2020
- Kyowa Hakko Bio Hit with 18-Day Biz Suspension over GMP Failings
December 25, 2019
BUSINESS
- AGC Biologics Launches Bispecific Antibody CDMO Project in Japan
May 28, 2026
- Bayer Regulatory Chief Hails Japan’s Review System, Flexibility on PI Waivers
May 28, 2026
- Asahi Kasei Licenses ADC Technology from Noguchi Institute
May 28, 2026
- Kissei Files Rigel’s AML Drug Olutasidenib in Japan
May 28, 2026
- Japan OTC Market Falls 2.4% in April amid Weaker Inbound Demand: Intage
May 28, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…